Moleculin Biotech, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Moleculin Biotech, Inc. (MBRX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-24.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2021-03-24
- Moleculin Biotech, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-12-31 was $0.00.
- Moleculin Biotech, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- Moleculin Biotech, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-06-30 was $0.00.
- Moleculin Biotech, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-03-31 was $0.00, a 100.00% decline year-over-year.
- Moleculin Biotech, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- Moleculin Biotech, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $321.00K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|---|
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $0.00 derived: sum of 2 quarters · filed 2021-03-24 | $0.00 derived: sum of 3 quarters · filed 2021-03-24 | $0.00 10-K · filed 2021-03-24 | |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-12 | $0.00 derived: sum of 2 quarters · filed 2020-11-12 | $0.00 10-Q · filed 2020-11-12 | $0.00 derived: sum of 4 quarters · filed 2021-03-24 | |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-12 | $0.00 10-Q · filed 2020-08-12 | $0.00 derived: sum of 3 quarters · filed 2021-03-24 | $212.00K derived: sum of 4 quarters · filed 2021-03-24 | |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-11 | $0.00 derived: sum of 2 quarters · filed 2021-03-24 | $212.00K derived: sum of 3 quarters · filed 2021-03-24 | $212.00K derived: sum of 4 quarters · filed 2021-03-24 | |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-24 | $212.00K derived: sum of 2 quarters · filed 2021-03-24 | $212.00K derived: sum of 3 quarters · filed 2021-03-24 | $321.00K 10-K · filed 2021-03-24 | |
| 2019-09-30 | $212.00K 10-Q · filed 2020-11-12 | $212.00K derived: sum of 2 quarters · filed 2020-11-12 | $321.00K 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-08-12 | $110.00K 10-Q · filed 2020-08-12 | |||
| 2019-03-31 | $110.00K 10-Q · filed 2020-05-11 | $106.00K 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |